ArticleFrontiers in oncology2026
Management of locally advanced lynch syndrome rectal cancer during pregnancy with neoadjuvant immunochemotherapy: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lynch syndrome (LS) is a hereditary cancer predisposition syndrome. Colorectal cancer during pregnancy is extremely rare, and LS-associated cases pose unique diagnostic and therapeutic challenges due to maternal-fetal and genetic considerations. Case presentation: A 37-year-old woman at 22 + 5 weeks of gestation presented with hematochezia. Ultrasonography and pelvic MRI revealed a 7.2 × 6.3 × 6.1 cm rectal mass with multiple enlarged pelvic lymph nodes posterior to the gravid uterus. Colonoscopy confirmed an ulcerative lesion 10 cm from the anal verge. Histopathology and immunohistochemistry (MLH1-/PMS2-/MSH2+/MSH6+) confirmed LS-associated rectal adenocarcinoma. Given the poor fetal viability and potential teratogenic effects of systemic therapy, medical termination was performed. The patient subsequently underwent neoadjuvant chemoradiotherapy (50.4 Gy in 28 fractions) combined with two cycles of capecitabine plus oxaliplatin (CapeOx) and tislelizumab, achieving significant tumor regression (yT2N0M0). Laparoscopic Dixon surgery revealed a 2.5 × 1.5 × 1.0 cm ulcerative lesion, corresponding to Tumor Regression Grade (TRG) 1. Six cycles of adjuvant CapeOx with tislelizumab were completed. No severe adverse events occurred, and at 24 months follow-up, the patient remains disease-free. Conclusion: LS-associated rectal cancer during pregnancy requires individualized, multidisciplinary management. Medical termination followed by neoadjuvant immunochemoradiotherapy can optimize maternal outcomes while minimizing fetal and genetic risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.